1184986-70-6
Chemical Structure
5,7-Dichlorokynurenic acid sodium
Synonym(s): 5,7-DCKA sodium
- CAS No.: 1184986-70-6
- Formula:C10H4Cl2NNaO3
- Molecular Weight:280.04
IUPAC Name: sodium 5,7-dichloro-4-hydroxyquinoline-2-carboxylate
InChIKey: VPRPMJHKWHCUFW-UHFFFAOYSA-M
SMILES: O=C(C1=NC2=CC(Cl)=CC(Cl)=C2C(O)=C1)O[Na]
Biological Activity: 5,7-Dichlorokynurenic acid (5,7-DCKA) sodium is a selective and competitive antagonist of the glycine site on NMDA receptor with a KB of 65 nM. 5,7-Dichlorokynurenic acid sodium reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid sodium increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid sodium exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
5,7-Dichlorokynurenic acid sodium | 5,7-Dichlorokynurenic acid (5,7-DCKA) sodium is a selective and competitive antagonist of the glycine site on NMDA receptor with a KB of 65 nM. 5,7-Dichlorokynurenic acid sodium reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid sodium increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid sodium exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. D McNamara, et al. 5,7-Dichlorokynurenic acid, a potent and selective competitive antagonist of the glycine site on NMDA receptors. Neurosci Lett. 1990 Nov 27;120(1):17-20. [Content Brief]
- [2]. Corbett R, et al. Effects of 5,7 dichlorokynurenic acid on conflict, social interaction and plus maze behaviors. Neuropharmacology. 1993;32(5):461-466. [Content Brief]
